AI播客：换个方式听新闻 下载mp3 音频由扣子空间生成 美国财政部长贝森特周二表示，美国今年迄今已获得约1000亿美元的关税收入，随着美国总统特朗普贸易战的征税加速，到 2025年底，这一数字可能增至3000亿美元。 贝森特在一次白宫内阁会议上说，特朗普新关税的主要征收工作仅在第二季度才开始，当时特朗普对美国进口商品实施了近乎 普遍的10%关税，并提高了对钢铁、铝和汽车的关税。 "因此我们可以预期，到年底，这个数字很可能远超3000亿美元，"贝森特说。 一位财政部发言人表示，3000亿美元的目标对应的是2025日历年的年底，即12月31日，而非政府财政年度的年底，即9月30 日。 要达到3000亿美元的2025年关税收入，将意味着美国未来几个月征收额的指数级增长，以及从当前水平上进行大幅和广泛的关 税上调。 贝森特补充说，国会预算办公室曾估计，关税收入在10年内将总计约2.8万亿美元，"我们认为这个数字可能偏低。" 财政部报告称，5月份的关税总额创下228亿美元的纪录，与去年同期的62亿美元相比，增长了近四倍。这使得美国2025财年前 八个月的关税征收总额达到861亿美元。截至2025日历年的前五个月，美国 ...

Market Performance - Major U.S. stock indices experienced significant gains, with the Dow Jones up 2.81%, Nasdaq up 4.35%, and S&P 500 up 3.26%, marking the highest closing levels since March [4][5] - The Nasdaq China Golden Dragon Index surged by 5.40%, reaching a new high since April 4, driven by strong performances from popular Chinese stocks [3][6] Economic Indicators - The New York Federal Reserve's second-quarter GDP real-time forecast increased to 2.42%, up from 2.34% the previous week, providing a favorable environment for major stock ETFs [4] - U.S. tariff revenue in April soared to a record $16.3 billion, an 86% increase from March's $8.75 billion and more than double the $7.1 billion from the same month last year [4] - Cumulative tariff revenue for the 2025 fiscal year reached $63.3 billion, over 18% higher than the same period in 2024 [4] Technology Sector - Major tech stocks saw substantial increases, with Amazon rising over 8%, Meta over 7%, and Apple, Tesla, and Nvidia all gaining over 5% [3][5] - Speculation surrounds Apple's potential price increase for the upcoming iPhone 17 series, with the current iPhone 16 series starting at $799 [5][6] Chinese Stocks - Notable gains in Chinese stocks included WeRide up over 27% and XPeng and Bilibili both rising nearly 8% [3][6] - WeRide announced a strategic partnership with Uber to expand autonomous Robotaxi services in 15 new cities over the next five years, with Uber committing an additional $100 million investment [6] Pharmaceutical Sector - The pharmaceutical sector saw collective gains, with Pfizer and Novo Nordisk both rising over 3% following Trump's signing of an executive order aimed at lowering prescription drug prices [7][8] - The executive order mandates that pharmaceutical companies provide "most favored nation pricing" to the U.S. market, aligning drug prices with those in other developed countries [8][9]